TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02559388
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (For Montelukast) Placebo pills manufactured for mimic 10 milligram montelukast pills
Study: NCT00395239
Drug: inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone; Budesonide; Ciclesonide Dosage and frequency is patient dependant.
Study: NCT01604343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 50.
Study: NCT01604343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 104.
Study: NCT04264286
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will prophylactic placebo after the end of the surgery
Study: NCT00820612
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg PR once at the time of ERCP
Study: NCT00436748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo solution for subcutaneous or intravenous injection to maintain the blind in the Q2W arm.
Study: NCT00661700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg placebo for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg placebo or down to 5mg placebo followed by 14 weeks placebo at preferred dose
Study: NCT00215046
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: drug - dosage is based on size of patient and frequency and duration is based on response to treatment.
Study: NCT01217918
Drug: 1 mg
Normalized name: biotin 1 MG
DrugBank: Biotin (DB00121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg or placebo a material sparing tablet per day for 10 days
Study: NCT01217918
Drug: 10 mg
Normalized name: biotin 10 MG
DrugBank: Biotin (DB00121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg or placebo as a material sparing tablet per day for 10 days
Study: NCT00414661
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.
Study: NCT00357370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, once daily, up to 12 weeks
Study: NCT03636750
Drug: HB002.1T
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB002.1T is a Vascular Endothelial Growth Factor Receptor Decoy
Study: NCT03096522
Drug: Phenytoin 2% spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will undergo anal fistulotomy then they will use phenytoin 2% spray topically on the anal wound resulting from fistulotomy with each sitz bath (twice per day) untill the anal wound heals completely
Study: NCT00783042
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open).
Study: NCT00783042
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral, once daily for 1 month (double blind)
Study: NCT01202825
Drug: TMC647055
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single dose as oral solution, doses from 100 mg up to a maximum of 3000 mg increasing in sessions I through VI.
Study: NCT01202825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
Study: NCT01202825
Drug: TMC647055
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution given in session XIII, treatment arm 1 during 10 days at a dose of 1000 mg every 12 hours.
Study: NCT01202825
Drug: TMC647055
Approvals — FDA: no, EMA: no, PMDA: no
Description: In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
Study: NCT01202825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
Study: NCT01202825
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule given in session XIII, in treatment arm 1 during 10 days and in treatment arm 2 during 6 days at a dose of 150 mg once daily.
Study: NCT01202825
Drug: TMC647055
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
Study: NCT01202825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
Study: NCT01202825
Drug: TMC647055
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
Study: NCT01988571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo tablet taken each morning orally for 24 months.
Study: NCT01964911
Drug: Ropivacaïne
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first 3 days, analgesic treatments will be provided, as usual, depending on pain intensity (EN \<3/10 : non opioids, EN 3-5/10 : weak opioids, EN\>5/10 : strong opioids).~If NRS is still over 5/10, continuous nerve block will be proposed. Patients will receive ropivacaïne, 5 mL/h during 7 days, with possibility of one bolus before wound care, through a stimulating catheter stimulong sono®.~In association, analgesic treatments will be provided, as usual, depending on pain intensity (as during the first 3 days).
Study: NCT02187302
Drug: CRLX101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02187302
Drug: Standard of Care (Investigator Choice)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00638703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00143611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resatorvid placebo-matching injection, subcutaneously for thirty minutes; then resatorvid placebo-matching injection, subcutaneously over 96 hours.
Study: NCT04358497
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NSAID treatment
Study: NCT03746522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection of placebo
Study: NCT00323414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gelcaps containing corn oil identical to the PUFA gelcaps 6 capsules-3 capsules by mouth 2x per day x 48 weeks
Study: NCT00606892
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar Pill
Study: NCT00606892
Drug: IV Nic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Nicotine given during the laboratory session following 4 days of exposure to the study medication (varenicline or placebo). This nicotine was given during each laboratory session which followed the 4 days of exposure to either placebo then varenicline or varenicline then placebo.
Study: NCT00804336
Drug: SOM230
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given subcutaneously twice a day for four weeks then given intramuscularly once every four weeks thereafter
Study: NCT00804336
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally once a day
Study: NCT03240627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cutaneous solution
Study: NCT03862391
Drug: Analgesics
Normalized name: ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: while patients are in the PACU after general anesthesia, if patients' VAS scores are higher than 3, we will give them 50 mg of deksketoprofen as analgesic.
Study: NCT03862391
Drug: Antiemetics
Normalized name: ANTIEMETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: while patients are in the PACU after general anesthesia, if patient' Nausea and vomiting scores are higher than 1, we will give them 4 mg of ondansetron
Study: NCT00648219
Drug: Benicar® Tablets 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg, single dose fed
Study: NCT00515827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg placebo tablet taken orally twice daily
Study: NCT02327923
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inj fentanyl 1.5mg/kg will be given at the time of induction.
Study: NCT02327923
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02442778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as capsules.
Study: NCT02442778
Drug: AVP-786-42.63
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42.63 mg of d6-DM and 4.9 mg of Q
Study: NCT01248299
Drug: FU-CDDP
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 21 days:~* Fluoro-uracil \[800 mg/m2, day 1 to day 5\]~* CisPlatin \[75 mg/m2, day 1 or day 2\]
Study: NCT01248299
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 14 days:~* Oxaliplatin \[85 mg/m2 by 2h infusion, day 1\]~* Fluoro-uracil \[400 mg/m2 as a bolus, day 1 and day 2\]~* Fluoro-uracil \[600 mg/m2, by 22h continous infusion, day 1 and day 2\]~* Elvorin \[500 mg/m2, day 1 and day 2\]
Study: NCT01248299
Drug: TPF
Normalized name: Docetaxel, Cisplatin, and Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 21 days:~* Docetaxel \[30 mg/m2, day 1 and day 8\]~* CisPlatin \[60 mg/m2, day 1\]~* Fluoro-uracil \[200 mg/m2/day by continous infusion\]~Or every 21 days:~* Docetaxel \[50 mg/m2, day 1\]~* CisPlatine \[70 mg/m2, day 1\]~* Fluoro-uracile \[700 mg/m2 /day, day 1 to day 5\]
Study: NCT02264002
Drug: Cilobradine low dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02264002
Drug: Cilobradine medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02264002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02213211
Drug: Artemether lumefantrine
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02643654
Drug: MABp1
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a sterile injectable liquid formulation of 50 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4). Each 10-mL serum vial contains 6 ml of the formulation, and is sealed with a 20-mm grey bromobutyl stopper and flip-off aluminum seal
Study: NCT02643654
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formulation buffer, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.
Study: NCT00605046
Drug: SPECT scan
Normalized name: spelt seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV151-01: Evaluation of \[123I\] AV151 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
Study: NCT02296814
Drug: Sinusitis Hevert SL Tablet
Normalized name: sinusitisinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
Study: NCT02296814
Drug: Placebo for Sinusitis Hevert SL Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
Study: NCT01387204
Drug: GSK1120212
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 2 mg dose is based on clinical data from the ongoing FTIH study in which subjects have been dosed daily for greater than 21 days, as well as preclinical toxicity data.
Study: NCT01247090
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in Group 3 will receive an equal volume of normal saline (placebo) infusion during their standard thrice-weekly dialysis treatments.
Study: NCT01891851
Drug: TMC435350 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive 200 mg (2 capsules) once daily orally from Day 1 to Day 7 in Session 1 and from Day 6 to Day 12 in Session 2
Study: NCT02076412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet PO bid (morning and evening)
Study: NCT03814954
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At first day of admission, patients will receive 3 doses of nebulized epinephrine every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
Study: NCT02484703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo PO BID. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
Study: NCT02484703
Drug: RO5186582
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 of 3 dosages of RO5186582 PO BID, including 40 mg, 60 mg, or 120 mg. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
Study: NCT00262067
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo consisted of the vehicle for bevacizumab without the antibody.
Study: NCT00262067
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles.~Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle~1. Docetaxel 75-100 mg/m\^2 IV~2. Paclitaxel protein-bound particles (Abraxane®) 260 mg/m\^2 IV~Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle~1. 5-fluorouracil 500 mg/m\^2 IV + epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~2. 5-fluorouracil 500 mg/m\^2 IV + doxorubicin 50 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~3. Doxorubicin 50-60 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~4. Epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~Capecitabine: 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle
Study: NCT03829046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 weeks of treatment
Study: NCT01547416
Drug: no epidural drug administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients allocated to general anesthesia group and DID NOT receive epidural anesthesia.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg.
Study: NCT01638962
Drug: Instruction on analgesic use for pain relief (acetaminophen and NSAIDs)
Normalized name: acetaminophen / diphenhydramine Oral Tablet [Unisom with Pain Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PHARMA group receives instruction, by video and pamphlet, on how to best use acetaminophen and NSAID as pain management for knee OA.
Study: NCT00858871
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, twice Daily, Until disease progression or unacceptable toxicity
Study: NCT00858871
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, Once Daily, Until disease progression or unacceptable toxicity
Study: NCT03736850
Drug: CS3006
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s).
Study: NCT02617550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 14 +/-3 days given as 1 or 2 tablets \[o.d.\].
Study: NCT03346122
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Study: NCT01589432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo capsules
Study: NCT00095758
Drug: Antidepressant + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
Study: NCT00758628
Drug: Bromefenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac BID 3 months
Study: NCT01660412
Drug: Standard of Care First
Normalized name: Standard ANSI First Aid KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the second injection, and randomly after that, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to \~7.40.
Study: NCT04063033
Drug: IV iron - Sodium Ferric Gluconate Complex
Normalized name: sodium ferric gluconate complex
DrugBank: Sodium ferric gluconate complex (DB09517)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Iron will be administered 125 mg each day, to 3-5 days during hospitalisation.
Study: NCT00665600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo TID
Study: NCT03551210
Drug: Placebo (250 ml)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl (250 ml), solution for infusion
Study: NCT03551210
Drug: Placebo (100 ml)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl (100 ml), solution for infusion
Study: NCT03108248
Drug: ethiodized oil; doxorubicin;Gelfoam;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional TACE was performed in both groups as follows. First, multiple angiographies were performed to detect the hepatic arterial anatomy and the possible feeding arteries of tumor, selective catheterization of the artery feeding the tumors was performed. A mixture of ethiodized oil was injected, followed by injection of Gelfoam particles.
Study: NCT00095797
Drug: R(+)XK469
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03228134
Drug: Ke Chuan Liu Wei Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine
Study: NCT00947297
Drug: HPN-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4 mL) delivers equivalent of PBA that 40 tablets of NaPBA do.
Study: NCT00003217
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003217
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003217
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002510
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03132051
Drug: steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide
Study: NCT04380857
Drug: Topical Prednisolone Acetate Ophthalmic Drops
Normalized name: prednisolone acetate Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Prednisolone acetate ophthalmic drops per standard of care:~Every two hours on day of procedure, then four times a day for the first week, then two times a day for the second week, then discontinue
Study: NCT00514267
Drug: YM 155
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT00973791
Drug: Ringer's Lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's Lactate 8 ml/kg was given intravenously before or after spinal anesthesia in cesarean section
Study: NCT04734405
Drug: Prof-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prof-001 cream
Study: NCT01888497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, prior to bedtime on the night before performance testing
Study: NCT00983554
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testim 10g daily
Study: NCT04734405
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: ointment base to mimic Prof-001
Study: NCT04734405
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: encapsulated lactose powder to mimic 150 mg fluconazole capsule
Study: NCT01610596
Drug: Halobetasol Propionate Lotion 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply twice daily for 1-2 weeks, not to exceed 50 grams per week
Study: NCT01610596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01388829
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R3 lot
Study: NCT01388829
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R4 lot
Study: NCT00202904
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets matched to ezetimibe, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
Study: NCT00864162
Drug: Atlace® 10 mg capsules, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fed conditions
Study: NCT01276314
Drug: anti- TNF-a
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg BIW, SC
Study: NCT01276314
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-1.5 mg / kg / day
Study: NCT03202004
Drug: GSK2894512 1% cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 % (10 mg/g) GSK2894512 cream will be provided in tubes labeled in compliance with country requirements.